Table 4.
Three-year overall/cancer-specific displayed as percentage survival and percentage standard error (30-day mortality excluded) for each TNM stage stratified by SIG in both all patient and elective patient cohorts.
| All patients | ||||||
|---|---|---|---|---|---|---|
| OS | All patients (TNM-I–III) | TNM-II | TNM-III | |||
| SIG | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) |
| 0 | 562 | 88% (SE 1%) | 205 | 93% (SE 2%) | 194 | 82% (SE 3%) |
| 1 | 404 | 84% (SE 2%) | 180 | 87% (SE 2%) | 154 | 73% (SE 4%) |
| 2 | 313 | 76% (SE 2%) | 153 | 81% (SE 3%) | 118 | 65% (SE 4%) |
| 3 | 201 | 65% (SE 3%) | 102 | 75% (SE 4%) | 90 | 53% (SE 5%) |
| 4 | 166 | 60% (SE 4%) | 85 | 68% (SE 5%) | 77 | 48% (SE 6%) |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||
| CSS | All patients (TNM-I–III) | TNM-II | TNM-III | |||
|---|---|---|---|---|---|---|
| SIG | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) |
| 0 | 562 | 93% (SE 1%) | 205 | 97% (SE 1%) | 194 | 86% (SE 3%) |
| 1 | 404 | 90% (SE 2%) | 180 | 96% (SE 2%) | 154 | 80% (SE 3%) |
| 2 | 313 | 82% (SE 2%) | 153 | 87% (SE 3%) | 118 | 69% (SE 4%) |
| 3 | 201 | 73% (SE 3%) | 102 | 86% (SE 4%) | 90 | 58% (SE 5%) |
| 4 | 166 | 70% (SE 4%) | 85 | 80% (SE 5%) | 77 | 58% (SE 6%) |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||
| Elective patients | ||||||
|---|---|---|---|---|---|---|
| OS | All patients (TNM-I–III) | TNM-II | TNM-III | |||
| SIG | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) |
| 0 | 525 | 89% (SE 1%) | 188 | 93% (SE 2%) | 176 | 85% (SE 3%) |
| 1 | 341 | 84% (SE 2%) | 149 | 89% (SE 3%) | 124 | 73% (SE 4%) |
| 2 | 227 | 78% (SE 3%) | 111 | 84% (SE 3%) | 79 | 66% (SE 5%) |
| 3 | 97 | 66% (SE 5%) | 47 | 72% (SE 7%) | 43 | 56% (SE 8%) |
| 4 | 78 | 58% (SE 6%) | 40 | 65% (SE 8%) | 35 | 46% (SE 8%) |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||
| CSS | All patients (TNM-I–III) | TNM-II | TNM-III | |||
|---|---|---|---|---|---|---|
| SIG | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) | n | % 3-yr OS (% SE) |
| 0 | 525 | 94% (SE 1%) | 188 | 97% (SE 1%) | 176 | 88% (SE 2%) |
| 1 | 341 | 91% (SE 2%) | 149 | 97% (SE 1%) | 124 | 80% (SE 4%) |
| 2 | 227 | 85% (SE 2%) | 111 | 91% (SE 3%) | 79 | 70% (SE 5%) |
| 3 | 97 | 77% (SE 4%) | 47 | 89% (SE 5%) | 43 | 61% (SE 8%) |
| 4 | 78 | 74% (SE 5%) | 40 | 81% (SE 7%) | 35 | 63% (SE 9%) |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||
OS overall survival, CSS cancer-specific survival, SIG Systemic Inflammatory Grade, n number of patients, %3-year OS/CSS percentage 3-year overall/cancer-specific survival, %SE percentage standard error.